Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › arteriovenous fistula

Arteriovenous fistula

Part of Arteriovenous Malformations

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for arteriovenous fistula

7 trials tracked for arteriovenous fistula: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 140 citations.

7Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 1 Other / NA 3
  1. Phase 3 Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae Completed · 140 cited
  2. Phase 4 Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients Completed
  3. Phase 3 Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Completed
  4. Phase 2 An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access Completed
  5. N/A IN.PACT™ AV Access IDE Study Completed
  6. N/A Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae Completed
Show 1 more trials
  1. N/A Arteriovenous Fistula Cannulation Practices and Dialysis Adequacy Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Arteriovenous fistula: what the trials found

Clinical evidence for arteriovenous fistula management includes the use of topical Tranexamic Acid 5% with bacitracin 1.

The Lutonix DCB demonstrated a 71.4% Target Lesion Primary Patency (TLPP) at 6 months post-procedure, which was significantly higher than the comparison group (63%, p=0.0562). However, TLPP rates for this intervention showed a decline over time, reaching 36% at 24 months 2. Additionally, the Lutonix DCB was associated with a significantly higher number of participants achieving freedom from any serious adverse events involving the AV access circuit at 30 days post-procedure (138 vs. 130, p=0.002) 2.

Sirolimus was evaluated for fistula suitability for dialysis at 6 months (FSD6), showing no statistically significant difference between groups (74 vs. 76, p=0.2942) 3.

Recent results — preliminary, needs further review

  • SRM003 showed maturation rates of 96.6% and 85.7% at week 12 (p=0.1197) and 96.6% and 88.6% at week 26 (p=0.1962), with a mean time to maturation of 9 vs. 10 weeks (p=0.090) 4.
  • The EchoMark / EchoSure system achieved a technical success rate of 270 for determining blood flow, diameter, and depth measurements from baseline to 4 months 5.
  • IN.PACT AV DCB showed a significantly higher Target Lesion Primary Patency Rate through 6 months (125 vs. 88, p=<0.001) and a significant difference in the primary safety endpoint for serious adverse events (7 vs. 7, p=0.002) 7.

For the clinician treating this condition

  • Lutonix DCB provides superior protection against serious adverse events involving the AV access circuit at 30 days compared to the alternative 2.
  • While Lutonix DCB shows high initial patency, there is a notable decline in target lesion primary patency over a 24-month period 2.
  • Sirolimus does not show a statistically significant difference in fistula suitability for dialysis at 6 months compared to the control 3.

AI synthesis of 6 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review confirms clip anastomosis improves one and two year primary patency rates for arteriovenous fistula creation compared to suture methods
Nephrology Meta-analysis
Systematic review confirms clip anastomosis improves one and two year primary patency rates for arteriovenous fistula creation compared to suture methods Vascular Clips Outperform Sutures for Dialysis Access Longevity
A comprehensive meta-analysis of 2,964 patients indicates that clip anastomosis significantly enhances one-year and two-year primary patency…
• Clips keep dialysis access open longer than sutures • Helps kidney patients needing reliable treatment lifelines • Not ready for all clini…
May 6, 2026
Meta-analysis shows systemic heparinization reduces early patency loss in adult AVF or graft placement
Nephrology Meta-analysis
Meta-analysis shows systemic heparinization reduces early patency loss in adult AVF or graft placement Systemic heparin lowers early clot risk but raises bleeding danger for arm access patients
This meta-analysis evaluated systemic heparinization versus standard care in adults undergoing arm arteriovenous fistula or graft placement.
A large analysis shows systemic heparin cuts early clot risk for arm access but increases bleeding complications, requiring careful balance.
May 1, 2026